Form D · Pharmaceuticals
Kleo Pharmaceuticals, Inc.
New Haven, CT · CIK 0001700389
Offering snapshot reported Jan 15, 2019 · SEC filing
- Reported sold
- $21.2M Offering amount: $21.2M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 12, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 15, 2019 | Initial | $21,206,378 | No comparison | 19 | SEC filing |
| May 29, 2018 | Amendment | $13,531,612 | $2,531,612vs May 26, 2017 | 11 | SEC filing |
| May 26, 2017 | Amendment | $11,000,000 | -$8,403,470vs May 23, 2017 | 9 | SEC filing |
| May 23, 2017 | Initial | $19,403,470 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-330541
Source: Form D, filed Jan 15, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John W. Childs | Director |
| Declan Doogan | Director |
| Charles G. Drake | Director |
| Alexander Goor | Director |
| Douglas Manion | Director, Executive |
| Roy Prieb | Director, Executive |
| David Spiegel | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
25 Science Park, Suite 2 D 150 Munson St.
New Haven, CT, 06511
New Haven, CT, 06511